FLT1 and neoplasm: Several strategies were developed to destroy neoplastic vessels by targeting vascular endothelial growth factor receptor-1 (VEGFR-1) [181], VEGFR-2 [182,183,184], prostate-specific membrane antigen (PSMA) [185] or tumour endothelial marker 8, also known as anthrax toxin receptor 1 (TEM8/ANTXR1) [186] molecules to starve the tumour and enhance tumour infiltration.